Please assess the completion status of the following clinical trial:

Trial Title: An Open Study to Assess the Robustness of the CRC749 Inhaler

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females at least 12 years of age.~2. A clinical diagnosis for at least 12 weeks prior to screening of asthma or COPD and stable treatment.~3. Spirometry following salbutamol showing FEV1 ≥40% of predicted normal and FEV1/FVC ratio \<0.7 for COPD subjects.~4. Spirometry without salbutamol showing FEV1 ≥50% of predicted normal for asthma subjects.~5. Ability to use the CRC749 inhaler.~Exclusion Criteria:~1. Other chronic or active respiratory disorder or symptoms of, or treatment for a COPD or asthma exacerbation during the 28 days preceding screening.~2. History of long QT syndrome or screening ECG with QTcF greater than 480 milliseconds.~3. Current evidence of, or history within the 6 months prior to screening of unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, or myocardial infarction.~4. Subjects in whom Advair(R) Diskus(R) / Seretide(R) Accuhaler(R) are contra-indicated.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MGR001 (Type: EXPERIMENTAL): MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).